What are the benefits of working with an expert team with an open-door policy? In this Q&A, Stuart Logan, BD Manager at BioAgilytix Europe, shares how his colleagues have supported his professional development.
Methods for the detection of drug-induced antibodies have become much more sensitive, but the question remains to be answered: are antibodies at this low concentration level clinically relevant?
With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at BioAgilytix Europe, and Todd Lester, BPM at our USA HQ, discuss how they collaborate.
Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs.
Yang Liu, Associate Director at BioAgilytix Europe and a recent hire to our company, talks with us about his work experience thus far and how he is using his expertise to shape his role.
In this Team Q&A session, Dave Williams, Director, Bioanalytical Operations at BioAgilytix, talks with us about why he made the move from Kansas City to join the BioAgilytix team in 2017, and the ways in which his role has evolved in just one year.
To keep up with the rapidly evolving field of drug development, we must stay on the pulse of bioanalytical innovation. Our latest blog summarizes some of the latest industry articles our team has found noteworthy.
Regan Reynolds, Corporate Recruiter at BioAgilytix, shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS is diagnosed and treated in the USA.
In immunogenicity assessments, we ideally aim to see any drug-induced antibody. Therefore, the best method is one that is able to detect ADAs as sensitively and specifically as possible. We discuss how the Biacore™ T200 platform enables this level of analysis.
The rapidly changing bioanalytical industry can make it challenging for CROs to keep up with technology demands. However, organizations that establish strong and responsive partnerships with sponsor companies will be in the best position to deliver new value through new technology.
Services
Platforms
